"Etentamig demonstrates a remarkable 74% response rate in heavily pretreated multiple myeloma patients, significantly outperforming standard care and offering a potential paradigm shift in accessibility for advanced disease."
AbbVie has announced compelling topline results from its Phase 3 CERVINO study, revealing that the investigational drug etentamig has met both primary endpoints in patients with relapsed or refractory multiple myeloma. The trial, which enrolled 393 participants with triple-class exposed disease – meaning their cancer had resisted proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies – showed a substantial improvement in response rates and a significant reduction in the risk of disease progression or death compared to standard available therapies. The strength of these findings was such that an independent data monitoring committee recommended unblinding the trial at its first planned interim efficacy analysis.
Etentamig Achieves Superior Response Rates and Survival Benefits in Advanced Multiple Myeloma
The CERVINO study enrolled patients with advanced multiple myeloma who had previously undergone treatment with three major classes of drugs, signifying a particularly challenging patient population with limited therapeutic options. These individuals had received a median of three prior lines of therapy, underscoring the refractory nature of their disease. In this highly pretreated cohort, etentamig demonstrated an objective response rate (ORR) of 74.0 percent, a significant improvement over the 45.7 percent ORR observed in patients receiving the investigator’s choice of standard available therapies. This marked difference suggests a potent therapeutic effect of etentamig in a population that has historically faced poor prognoses.
Further bolstering the drug’s efficacy, etentamig reduced the risk of disease progression or death by a substantial 60 percent, as indicated by a progression-free survival (PFS) hazard ratio of 0.40. This benefit was consistent across all prespecified subgroups evaluated, highlighting the drug’s broad applicability. While the data cutoff for the primary analysis showed a 12-month overall survival (OS) of 87.9 percent for etentamig compared to 72.0 percent for standard care (hazard ratio of 0.48), AbbVie cautioned that the prespecified efficacy boundary for OS had not been crossed. Nevertheless, this OS data is highly encouraging and suggests a meaningful survival advantage for patients treated with etentamig.
Dosing Simplicity and Favorable Safety Profile May Enhance Accessibility
Beyond its impressive efficacy, the dosing schedule of etentamig presents a potentially transformative aspect for patient access. Administered once every four weeks following a single step-up dose, this regimen is designed to simplify treatment delivery, potentially enabling administration outside of highly specialized cancer centers. This is a critical consideration in the management of multiple myeloma, where the logistical challenges associated with complex therapies can act as a significant barrier to care, particularly for patients in rural or underserved areas.
Etentamig belongs to the class of bispecific T-cell engagers that are directed against B-cell maturation antigen (BCMA). These innovative therapies work by bridging the patient’s own T cells with myeloma cells, thereby activating the immune system to target and eliminate cancer cells. While BCMA-directed therapies, including CAR-T cell therapies, have revolutionized multiple myeloma treatment, their widespread adoption has been hampered by concerns regarding side effects and the extensive monitoring infrastructure required.
The CERVINO trial reported on the safety profile of etentamig, with a particular focus on cytokine release syndrome (CRS), a common and potentially serious inflammatory reaction associated with T-cell engaging therapies. Among patients who received a single step-up dose, CRS occurred in 28.3 percent, with the vast majority being grade 1 (mild), accounting for 23.9 percent of cases. Notably, no grade 3 or higher CRS events were reported, suggesting a manageable safety profile. Immune effector cell-associated neurotoxicity syndrome (ICANS) was also assessed, with one patient experiencing grade 1 ICANS and no higher-grade events.
Infections remain a concern in patients with multiple myeloma, particularly those undergoing aggressive treatment. Grade 3 or 4 infections occurred in 27.7 percent of etentamig patients compared to 19.2 percent of those on standard therapy, a difference consistent with known risks in this drug class. However, fatal infections were less common with etentamig (1.5 percent) than with standard care (3.1 percent). Furthermore, treatment-emergent adverse events leading to discontinuation were significantly lower with etentamig (3.6 percent) compared to standard therapy (9.6 percent), indicating a favorable tolerability profile.
Dr. Peter Voorhees, Chief of the Plasma Cell Disorders Division at Atrium Health Levine Cancer Institute and an investigator on the trial, emphasized the potential of etentamig to broaden access. He stated that the findings support the drug as a BCMA-targeted bispecific option with "the potential to provide access across a range of treatment settings," suggesting that its simpler administration could facilitate its use in community oncology practices.
Contextualizing the Findings: Data Limitations and Future Implications
While the topline results of the CERVINO study are highly promising, it is crucial to acknowledge certain limitations. These findings represent preliminary data announced by the manufacturer and have not yet undergone peer review. The full data set is slated for presentation at the International Myeloma Society Annual Meeting in Glasgow, Scotland, later this month, where it will be scrutinized by the scientific community.
The CERVINO trial was conducted in an open-label manner, meaning both patients and investigators were aware of the treatment assignments. While this design is often necessary in trials comparing multiple complex regimens, it can introduce potential biases in subjective outcome assessments. Furthermore, these results are derived from an interim efficacy analysis. It is not uncommon for observed differences between treatment arms to moderate as follow-up time lengthens, especially in chronic diseases like multiple myeloma where patients can live for many years after disease recurrence. The median follow-up in this study was 11.4 months, which is relatively short for a disease with long-term survival potential.
Etentamig is currently an investigational drug and has not received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA). AbbVie intends to engage with global regulatory authorities to discuss these results and determine the path forward for potential approval. As of now, etentamig is only accessible through clinical trials, and the CERVINO study is listed on ClinicalTrials.gov. An earlier first-in-human study of the same molecule was published in 2022, providing initial insights into its safety and pharmacokinetics.
The composition of the comparison arm also warrants consideration. Patients receiving standard care were treated with one of three physician-selected combination regimens: carfilzomib plus dexamethasone, elotuzumab plus pomalidomide and dexamethasone, or selinexor plus bortezomib and dexamethasone. While this approach reflects real-world clinical practice, it results in a less uniform control group compared to a trial where all patients receive a single, standardized treatment.
Addressing Access Barriers and the Future of Multiple Myeloma Care
Multiple myeloma is a malignant proliferation of plasma cells in the bone marrow. While typically manageable, it is generally not curable, necessitating sequential lines of therapy as the disease progresses. For patients who have exhausted the efficacy of the three principal drug classes, treatment options become increasingly limited, and prognoses worsen significantly.
Geographical location plays a pivotal role in a patient’s ability to access advanced therapies. Bispecific antibodies and CAR-T cell therapies have largely been concentrated in major medical centers equipped to manage complex side effects like CRS and provide intensive monitoring. This concentration has been identified as a significant barrier to the integration of these groundbreaking treatments into community oncology practices, forcing patients in smaller cities and rural areas to incur substantial travel, lodging, and time-away-from-work costs.
A monthly injection regimen with predominantly mild CRS represents a profile that could potentially decentralize care and bring advanced treatment options closer to patients’ homes, provided the efficacy and safety findings are validated and regulatory approval is granted. These are significant "ifs" that will require further data and regulatory review to resolve.
Patients and their caregivers who have questions regarding the appropriateness of clinical trials or the potential implications of these findings should consult with their treating hematologist or oncologist. It is imperative to reiterate that these results do not alter current treatment recommendations, and no patient should discontinue or alter their existing therapeutic regimen based solely on this preliminary announcement.
Key Questions Answered:
What is etentamig?
Etentamig is an investigational second-generation bispecific antibody designed to engage the patient’s immune T cells to target BCMA, a protein found on multiple myeloma cells. It is not currently approved by any regulatory authority.
What did the trial show?
In the Phase 3 CERVINO study involving 393 patients, 74.0 percent responded to etentamig compared to 45.7 percent on standard therapies. The drug also reduced the risk of disease progression or death by 60 percent.
Who was studied?
The trial enrolled patients with relapsed or refractory multiple myeloma who had previously received at least two prior lines of therapy, including treatments from three major drug classes. The median number of prior therapies was three.
How serious were the side effects?
Cytokine release syndrome (CRS) occurred in 28.3 percent of patients receiving a single step-up dose, with most cases being mild (grade 1). No grade 3 or higher CRS events were reported. Serious infections were more common than with standard care.
Are these results peer-reviewed?
No. These are topline results announced by the manufacturer. Comprehensive data are scheduled for presentation at a major myeloma conference later this month.
When could patients get this drug?
There is no established timeline for patient access. AbbVie plans to discuss the results with regulatory authorities to determine the next steps. Approval would necessitate a formal submission and review process, and the drug remains investigational and available only through clinical trials.
Should any patient change treatment because of this?
No. Current treatment recommendations remain unchanged. Patients considering trial eligibility should discuss this with their hematologist or oncologist.
